CO2020015255A2 - Métodos y composiciones para tratar el cáncer - Google Patents
Métodos y composiciones para tratar el cáncerInfo
- Publication number
- CO2020015255A2 CO2020015255A2 CONC2020/0015255A CO2020015255A CO2020015255A2 CO 2020015255 A2 CO2020015255 A2 CO 2020015255A2 CO 2020015255 A CO2020015255 A CO 2020015255A CO 2020015255 A2 CO2020015255 A2 CO 2020015255A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- methods
- treating cancer
- cancer
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Abstract
RESUMEN Se proporcionan en el presente documento, en algunas realizaciones, métodos y composiciones (por ejemplo, composiciones de células) para el tratamiento del cáncer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670417P | 2018-05-11 | 2018-05-11 | |
US201862701340P | 2018-07-20 | 2018-07-20 | |
US201862756643P | 2018-11-07 | 2018-11-07 | |
US201862773658P | 2018-11-30 | 2018-11-30 | |
US201962826600P | 2019-03-29 | 2019-03-29 | |
PCT/IB2019/000500 WO2019215500A1 (en) | 2018-05-11 | 2019-05-10 | Methods and compositions for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020015255A2 true CO2020015255A2 (es) | 2021-01-29 |
Family
ID=67402964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0015255A CO2020015255A2 (es) | 2018-05-11 | 2020-12-04 | Métodos y composiciones para tratar el cáncer |
Country Status (16)
Country | Link |
---|---|
US (4) | US20210060072A1 (es) |
EP (1) | EP3790629A1 (es) |
JP (1) | JP2021522820A (es) |
KR (1) | KR20210008502A (es) |
CN (1) | CN112105420A (es) |
AU (1) | AU2019266398A1 (es) |
BR (1) | BR112020022879A2 (es) |
CA (1) | CA3099364A1 (es) |
CL (1) | CL2020002914A1 (es) |
CO (1) | CO2020015255A2 (es) |
MX (1) | MX2020012028A (es) |
PE (1) | PE20210666A1 (es) |
PH (1) | PH12020551923A1 (es) |
SG (1) | SG11202011080QA (es) |
WO (1) | WO2019215500A1 (es) |
ZA (1) | ZA202006627B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020267057A1 (en) | 2019-04-30 | 2021-11-18 | Crispr Therapeutics Ag | Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 |
JP2022538836A (ja) | 2019-06-27 | 2022-09-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | がんを治療するためのキメラ抗原受容体t細胞及びnk細胞阻害剤の使用 |
WO2021044378A1 (en) | 2019-09-06 | 2021-03-11 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
IL292467A (en) | 2019-11-13 | 2022-06-01 | Crispr Therapeutics Ag | Treatment of hematopoietic cell cancers using genetically engineered t cells targeting cd70 |
IL292468A (en) | 2019-11-13 | 2022-06-01 | Crispr Therapeutics Ag | Treatment of renal cell carcinoma using genetically engineered t cells targeting cd70 |
IL292329A (en) | 2019-11-13 | 2022-06-01 | Crispr Therapeutics Ag | Manufacturing process for preparing t cells expressing chimeric antigen receptors |
TW202132560A (zh) | 2019-11-13 | 2021-09-01 | 瑞士商Crispr治療公司 | 製備car-t細胞之方法 |
CA3158114A1 (en) | 2019-11-13 | 2021-05-20 | Jonathan Alexander Terrett | Cd70+ solid tumor therapy using genetically engineered t cells targeting cd70 |
CN113087805A (zh) * | 2019-12-31 | 2021-07-09 | 华东师范大学 | 一种共表达免疫调节分子的嵌合抗原受体t细胞的制备及其应用 |
JP2023512469A (ja) | 2020-01-17 | 2023-03-27 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 癌療法におけるbcma特異的キメラ抗原受容体を発現する遺伝子改変t細胞及びその使用 |
AU2021221277A1 (en) | 2020-02-11 | 2022-08-25 | Crispr Therapeutics Ag | Anti-idiotype antibodies targeting anti-CD19 chimeric antigen receptor |
GB202005184D0 (en) * | 2020-04-08 | 2020-05-20 | Autolus Ltd | Method |
TW202208412A (zh) | 2020-05-06 | 2022-03-01 | 瑞士商Crispr治療公司 | 對酪胺酸蛋白激酶樣7(ptk7)特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞 |
US20210363212A1 (en) | 2020-05-21 | 2021-11-25 | Crispr Therapeutics Ag | Genetically engineered car t cells that secret interleukin-12 and therapeutic uses thereof |
US20210380707A1 (en) | 2020-06-04 | 2021-12-09 | Crispr Therapeutics Ag | Anti-cd70 antibodies and uses thereof |
US20220023344A1 (en) | 2020-06-26 | 2022-01-27 | Crispr Therapeutics Ag | Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19 |
US11795238B2 (en) | 2020-08-04 | 2023-10-24 | Crispr Therapeutics Ag | Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor |
WO2022043861A1 (en) | 2020-08-25 | 2022-03-03 | Crispr Therapeutics Ag | Anti-idiotype antibodies targeting anti-bcma chimeric antigen receptor |
MX2023003365A (es) | 2020-09-23 | 2023-03-29 | Crispr Therapeutics Ag | Linfocitos t modificados por ingenieria genetica con disrupcion de regnasa-1 y/o tgfbrii tienen una funcionalidad y una persistencia mejoradas. |
JP2023546178A (ja) | 2020-10-20 | 2023-11-01 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Cd19を標的とする遺伝子操作されたt細胞を用いたb細胞悪性腫瘍の同種他家細胞療法 |
AU2021370652A1 (en) * | 2020-10-26 | 2023-06-08 | Memorial Hospital For Cancer And Allied Diseases | Cells with cd70 knockout and uses for immunotherapy |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
US20220193134A1 (en) | 2020-12-23 | 2022-06-23 | Crispr Therapeutics Ag | Co-use of lenalidomide with car-t cells |
US20220202859A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
US20220288122A1 (en) | 2021-03-09 | 2022-09-15 | Crispr Therapeutics Ag | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
WO2022215978A1 (ko) * | 2021-04-05 | 2022-10-13 | 주식회사 셀렌진 | Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도 |
WO2022238963A2 (en) | 2021-05-12 | 2022-11-17 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating solid tumors |
AR125851A1 (es) * | 2021-05-12 | 2023-08-16 | Crispr Therapeutics Ag | Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas |
WO2023007373A1 (en) | 2021-07-26 | 2023-02-02 | Crispr Therapeutics Ag | Methods for manufacturing genetically engineered car-t cells |
US20230128917A1 (en) | 2021-09-14 | 2023-04-27 | Crispr Therapeutics Ag | Genetically engineered immune cells having a disrupted cd83 gene |
WO2023084399A1 (en) | 2021-11-09 | 2023-05-19 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7 |
WO2023100153A1 (en) | 2021-12-03 | 2023-06-08 | Crispr Therapeutics Ag | Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy |
WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
WO2023119201A2 (en) | 2021-12-22 | 2023-06-29 | Crispr Therapeutics Ag | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof |
WO2023123195A1 (zh) * | 2021-12-30 | 2023-07-06 | 深圳市先康达生命科学有限公司 | 一种目的基因可调控的工程化免疫细胞及其制备方法和应用 |
CN114369622A (zh) * | 2021-12-31 | 2022-04-19 | 西安桑尼赛尔生物医药有限公司 | 同时靶向cd7和cd19的双特异通用型car-t细胞及其制备方法 |
WO2023201288A1 (en) * | 2022-04-15 | 2023-10-19 | The General Hospital Corporation | Cd70 binding car-t cells comprising cd33 binding t-cell engaging antibody molecules |
WO2023205148A1 (en) | 2022-04-19 | 2023-10-26 | Intellia Therapeutics, Inc. | Chimeric antigen receptor compositions and uses |
WO2023248126A1 (en) | 2022-06-20 | 2023-12-28 | Crispr Therapeutics Ag | Chimeric antigen receptor specific to cd117 |
WO2023248125A1 (en) | 2022-06-20 | 2023-12-28 | Crispr Therapeutics Ag | Cd117-targeting nanoparticles for use in drug delivery |
WO2024023802A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene |
WO2024023801A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene |
WO2024023804A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
HU227008B1 (en) | 1999-08-17 | 2010-04-28 | Apotech R & D Sa | Use of baff receptor (bcma) as an immunoregulatory agent |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
MXPA02008265A (es) | 2000-02-24 | 2004-09-10 | Xcyte Therapies Inc | Concentracion y estimulacion simultanea de calulas. |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
EP2301971A1 (en) | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antibodies that bind both BCMA and TACI |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス, インコーポレイテッド | 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
DE10328289B3 (de) | 2003-06-23 | 2005-01-05 | Enginion Ag | Arbeitsmedium für Dampfkreisprozesse |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
CA2583208C (en) | 2004-10-15 | 2015-08-25 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US20120294863A1 (en) | 2004-10-15 | 2012-11-22 | Seattle Genetics, Inc. | Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders |
US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
WO2006060878A1 (en) | 2004-12-10 | 2006-06-15 | Peter Maccallum Cancer Institute | Methods and compositions for adoptive immunotherapy |
CN101203241B (zh) | 2005-04-19 | 2012-02-22 | 西雅图基因公司 | 人源化抗-cd70结合物和其应用 |
US7700739B2 (en) | 2005-06-30 | 2010-04-20 | Abbott Laboratories | IL-12/p40 binding proteins |
EP1934261B1 (en) | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
KR20090088946A (ko) * | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | 씨디70에 결합하는 인간 항체 및 이의 용도 |
EP2141997B1 (en) | 2007-03-30 | 2012-10-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
US7771720B2 (en) | 2007-09-07 | 2010-08-10 | Cisthera, Inc. | Humanized PAI-1 antibodies |
CN102056626B (zh) | 2008-04-11 | 2016-07-06 | 西雅图遗传学公司 | 胰腺癌、卵巢癌和其它癌症的检测和治疗 |
JP5425775B2 (ja) | 2008-06-30 | 2014-02-26 | 協和発酵キリン株式会社 | 抗cd27抗体 |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
TR201815882T4 (tr) | 2009-12-10 | 2018-11-21 | Univ Iowa State Res Found Inc | Tal efektörü aracılı dna modifikasyonu. |
EP2520589B1 (en) | 2009-12-29 | 2018-11-07 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
PL2542590T5 (pl) | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych |
JP6002659B2 (ja) | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトcd27に結合する抗体およびその使用 |
US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
WO2012004367A1 (en) | 2010-07-09 | 2012-01-12 | N.V. Organon | Agonistic antibody to cd27 |
EP3372244A3 (en) * | 2010-10-27 | 2018-10-24 | Baylor College of Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
JP5947311B2 (ja) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変t細胞の使用 |
TR201807202T4 (tr) | 2011-03-16 | 2018-06-21 | Argenx Bvba | CD70 antikorları. |
MX351069B (es) | 2011-05-27 | 2017-09-29 | Glaxo Group Ltd | Proteinas de union abcma (cd269/tnfrsf17). |
US9382319B2 (en) | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
CA2854720C (en) | 2011-11-11 | 2018-12-18 | Rinat Neuroscience Corp. | Antibodies specific for trop-2 and their uses |
US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
KR20130060720A (ko) | 2011-11-30 | 2013-06-10 | 한국전자통신연구원 | 목적 기반 시맨틱 서비스 디스커버리를 위한 서비스 목적 해석 장치 및 방법 |
NZ629697A (en) | 2012-03-15 | 2017-01-27 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods and uses |
BR112014024893B8 (pt) | 2012-04-11 | 2022-09-06 | Us Health | Sequência de ácido nucleico isolada ou purificada que codifica um receptor de antígeno quimérico (car) e seu uso, cars isolados ou purificados, vetores, métodos para destruir células cancerígenas e polinucleotídeo |
SG11201407802WA (en) | 2012-05-25 | 2015-01-29 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
JP6694712B2 (ja) | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Cd269(bcma)に対する抗体 |
JP2016507523A (ja) | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | CD3εおよびBCMAに対する二重特異的抗体 |
WO2014158821A1 (en) | 2013-03-12 | 2014-10-02 | Imaginab, Inc. | Antigen binding constructs to cd70 |
KR102274714B1 (ko) | 2013-03-13 | 2021-07-09 | 씨젠 인크. | 사이클로덱스트린 및 항체-약물 포합체 제형 |
WO2014140374A2 (en) | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Monovalent cd27 antibodies |
CN105208866B (zh) | 2013-03-21 | 2018-11-23 | 桑格摩生物治疗股份有限公司 | 使用工程化锌指蛋白核酸酶靶向断裂t细胞受体基因 |
EP2981617B1 (en) | 2013-04-04 | 2023-07-05 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
EP3309248B1 (en) | 2013-05-29 | 2021-06-09 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
KR20220119176A (ko) | 2014-02-04 | 2022-08-26 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
ES2711498T3 (es) * | 2014-02-14 | 2019-05-06 | Cellectis | Células para inmunoterapia diseñadas mediante ingeniería genética para dirigir un antígeno presente en células inmunitarias y células patológicas |
WO2015134877A1 (en) | 2014-03-07 | 2015-09-11 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
DK3693384T3 (da) * | 2014-03-11 | 2024-04-15 | Cellectis | Fremgangsmåde til at generere T-celler med kompatibilitet for allogen transplantation |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
AU2015247323B2 (en) * | 2014-04-18 | 2021-07-01 | Editas Medicine, Inc. | CRISPR-Cas-related methods, compositions and components for cancer immunotherapy |
US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
US10287350B2 (en) * | 2014-06-02 | 2019-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting CD-19 |
WO2015188056A1 (en) | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
AU2015295346A1 (en) | 2014-07-29 | 2017-02-16 | Allogene Therapeutics, Inc. | EGFRvlll specific chimeric antigen receptors for cancer immunotherapy |
WO2016025454A2 (en) | 2014-08-12 | 2016-02-18 | Anthrogenesis Corporation | Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract |
GB201418965D0 (es) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
EP3215168B1 (en) * | 2014-10-31 | 2023-08-02 | The Trustees of the University of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
US20180141992A1 (en) | 2014-11-06 | 2018-05-24 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
WO2016089433A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
DK3227432T3 (en) | 2014-12-05 | 2023-10-23 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
EP3230310B1 (en) * | 2014-12-08 | 2019-06-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd70 chimeric antigen receptors |
HRP20211648T1 (hr) | 2014-12-12 | 2022-02-04 | 2Seventy Bio, Inc. | Kimerni receptori antigena bcma |
CN108064252A (zh) | 2014-12-19 | 2018-05-22 | 达纳-法伯癌症研究所公司 | 嵌合抗原受体及其使用方法 |
JP2018504143A (ja) | 2015-01-26 | 2018-02-15 | セレクティスCellectis | がん免疫治療のための抗hsp70特異的キメラ抗原受容体(car) |
GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
US20160348073A1 (en) | 2015-03-27 | 2016-12-01 | President And Fellows Of Harvard College | Modified t cells and methods of making and using the same |
AU2016246450B2 (en) | 2015-04-06 | 2022-03-17 | Agilent Technologies, Inc. | Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation |
US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
JP2018515139A (ja) | 2015-05-08 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 万能ドナー幹細胞および関連する方法 |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2017222593A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
EP3328399B1 (en) | 2015-07-31 | 2023-12-27 | Regents of the University of Minnesota | Modified cells and methods of therapy |
EP3355937A4 (en) | 2015-09-28 | 2019-04-17 | Regents of the University of Minnesota | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY |
DK3359184T3 (da) | 2015-10-05 | 2020-06-15 | Prec Biosciences Inc | Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor |
GB201518136D0 (en) | 2015-10-14 | 2015-11-25 | Glaxosmithkline Ip Dev Ltd | Novel chimeric antigen receptors |
WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
BR112018008326A2 (pt) | 2015-10-30 | 2018-10-30 | Aleta Biotherapeutics Inc. | composições e métodos para o tratamento de câncer |
KR20190008171A (ko) | 2015-11-13 | 2019-01-23 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항-bcma 폴리펩티드 및 단백질 |
SG11201804373VA (en) | 2015-12-04 | 2018-06-28 | Novartis Ag | Compositions and methods for immunooncology |
US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
WO2017106537A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the mhc cell receptor |
CN108778297B (zh) | 2015-12-18 | 2024-02-09 | 桑格摩生物治疗股份有限公司 | T细胞受体的靶向破坏 |
CA3009637A1 (en) | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
ITUB20160112A1 (it) | 2016-01-28 | 2016-04-28 | Serteaweb Srl | Processo di allarme e sistema televisivo relativo ad un tale processo di allarme |
WO2017143069A1 (en) | 2016-02-17 | 2017-08-24 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
JP2019509738A (ja) | 2016-03-11 | 2019-04-11 | ブルーバード バイオ, インコーポレイテッド | ゲノム編集された免疫エフェクター細胞 |
BR112018070073A2 (pt) | 2016-04-01 | 2019-02-12 | Kite Pharma, Inc. | receptores de antígeno quimérico e célula t e métodos de uso |
EP3436059B1 (en) | 2016-04-01 | 2022-01-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
CA3020330A1 (en) | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
CA3020993A1 (en) | 2016-04-14 | 2017-10-19 | Bluebird Bio, Inc. | Salvage chimeric antigen receptor systems |
JP2019514870A (ja) * | 2016-04-22 | 2019-06-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | B細胞悪性腫瘍の処置のための方法及びワクチン組成物 |
US11141471B2 (en) * | 2016-04-25 | 2021-10-12 | Regen BioPharma, Inc. | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells |
US10875919B2 (en) | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
EP3463396A1 (en) | 2016-06-07 | 2019-04-10 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
WO2018068257A1 (zh) | 2016-10-13 | 2018-04-19 | 北京艺妙神州医疗科技有限公司 | 通用型car-t细胞及其制备方法和用途 |
WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
WO2018132479A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Modified t cells and methods of their use |
AU2018367896B2 (en) * | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
EP3746483A1 (en) | 2018-02-01 | 2020-12-09 | Pfizer Inc | Chimeric antigen receptors targeting cd70 |
US11957695B2 (en) * | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
-
2019
- 2019-05-10 CN CN201980031761.4A patent/CN112105420A/zh active Pending
- 2019-05-10 AU AU2019266398A patent/AU2019266398A1/en active Pending
- 2019-05-10 SG SG11202011080QA patent/SG11202011080QA/en unknown
- 2019-05-10 US US17/054,483 patent/US20210060072A1/en active Pending
- 2019-05-10 MX MX2020012028A patent/MX2020012028A/es unknown
- 2019-05-10 PE PE2020001838A patent/PE20210666A1/es unknown
- 2019-05-10 US US16/409,737 patent/US20200063100A1/en not_active Abandoned
- 2019-05-10 EP EP19742890.7A patent/EP3790629A1/en active Pending
- 2019-05-10 WO PCT/IB2019/000500 patent/WO2019215500A1/en active Application Filing
- 2019-05-10 JP JP2020563430A patent/JP2021522820A/ja active Pending
- 2019-05-10 KR KR1020207035240A patent/KR20210008502A/ko unknown
- 2019-05-10 BR BR112020022879-6A patent/BR112020022879A2/pt unknown
- 2019-05-10 CA CA3099364A patent/CA3099364A1/en active Pending
-
2020
- 2020-10-23 ZA ZA2020/06627A patent/ZA202006627B/en unknown
- 2020-11-10 CL CL2020002914A patent/CL2020002914A1/es unknown
- 2020-11-11 PH PH12020551923A patent/PH12020551923A1/en unknown
- 2020-12-04 CO CONC2020/0015255A patent/CO2020015255A2/es unknown
-
2021
- 2021-04-23 US US17/238,729 patent/US11254912B2/en active Active
- 2021-04-23 US US17/238,741 patent/US11649438B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20200063100A1 (en) | 2020-02-27 |
AU2019266398A1 (en) | 2020-11-19 |
US20210261919A1 (en) | 2021-08-26 |
ZA202006627B (en) | 2022-03-30 |
CA3099364A1 (en) | 2019-11-14 |
CL2020002914A1 (es) | 2021-07-30 |
WO2019215500A1 (en) | 2019-11-14 |
MX2020012028A (es) | 2021-03-29 |
BR112020022879A2 (pt) | 2021-02-23 |
EP3790629A1 (en) | 2021-03-17 |
JP2021522820A (ja) | 2021-09-02 |
KR20210008502A (ko) | 2021-01-22 |
US11649438B2 (en) | 2023-05-16 |
PH12020551923A1 (en) | 2021-06-14 |
PE20210666A1 (es) | 2021-03-31 |
US11254912B2 (en) | 2022-02-22 |
US20210060072A1 (en) | 2021-03-04 |
CN112105420A (zh) | 2020-12-18 |
US20210246425A1 (en) | 2021-08-12 |
SG11202011080QA (en) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
DOP2019000266A (es) | Inhibidores de pd-1/pd-l1 | |
BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
GB2557123A (en) | Modified cells and methods of therapy | |
CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
CO2021006493A2 (es) | Terapia del cáncer con células inmunitarias anti-liv1 | |
CO2021005471A2 (es) | Terapia del cáncer con células inmunitarias anti-ptk7 | |
BR112018009745A2 (pt) | compostos heterocíclicos para o tratamento de doença | |
AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
PH12021550035A1 (en) | Combination therapy | |
EA201992875A1 (ru) | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения |